going from tirzepatide to retatrutide Switching and What You Should Know Before Making the Change Comparing the Big 3, Semaglutide,
Description
The study was published in JACC: Clinical Electrophysiology and presented at the American College of Cardiology Scientific Session.

Understanding the underlying mechanisms, your individual biomarker profile, and evidence-based management strategies can help you have a more informed conversation with your healthcare provider about optimizing your treatment e
Constitutive hGPR17L activity inhibited GLP-1 secretion, and MDL29,951 treatment further inhibited this secretion, which was attenuated by treatment with the GPR17 antagonist HAMI3379

In intensification scenarios, both switching and dose escalation strategies improved weight loss, although the probability of achieving2 additional percentage points varied across regimens

Another two longer-acting analogs, glepaglutide and apraglutide, are currently undergoing phase III clinical trials

Yes 30% patients - bile acids, gut microbiome, GLP-1 surge
